Axogen, Inc. to Present at the Cantor Fitzgerald Global Healthcare Conference
September 19 2019 - 7:00AM
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and
marketing innovative surgical solutions for damage or discontinuity
to peripheral nerves, today announced that Karen Zaderej, chairman,
chief executive officer, and president, will present at the Cantor
Fitzgerald Global Healthcare Conference in New York City. The
presentation is scheduled for October 2, 2019 at 1:15 p.m. ET.
The presentation will be webcast live and can be accessed
through the Investors page at www.axogeninc.com. For those not
available to listen to the live broadcast, a replay will be
archived for 90 days and available through the Investors page on
www.axogeninc.com.
About AxogenAxogen (AXGN) is the leading
company focused specifically on the science, development and
commercialization of technologies for peripheral nerve regeneration
and repair. We are passionate about helping to restore peripheral
nerve function and quality of life to patients with physical damage
or transection to peripheral nerves by providing innovative,
clinically proven and economically effective repair solutions for
surgeons and health care providers. Peripheral nerves provide the
pathways for both motor and sensory signals throughout the body.
Every day, people suffer traumatic injuries or undergo surgical
procedures that impact the function of their peripheral
nerves. Physical damage to a peripheral nerve, or the
inability to properly reconnect peripheral nerves, can result in
the loss of muscle or organ function, the loss of sensory feeling,
or the initiation of pain.
Axogen's platform for peripheral nerve repair features a
comprehensive portfolio of products, including Avance® Nerve Graft,
a biologically active off-the-shelf processed human nerve allograft
for bridging severed peripheral nerves without the comorbidities
associated with a second surgical site; Axoguard® Nerve Connector,
a porcine submucosa extracellular matrix (ECM) coaptation aid for
tensionless repair of severed peripheral nerves; Axoguard® Nerve
Protector, a porcine submucosa ECM product used to wrap and protect
damaged peripheral nerves and reinforce the nerve reconstruction
while preventing soft tissue attachments; and Avive® Soft
Tissue Membrane, a minimally processed human umbilical cord
membrane that may be used as a resorbable soft tissue covering to
separate tissue layers and modulate inflammation in the surgical
bed. Along with these core surgical products, Axogen also offers
Acroval® Neurosensory & Motor Testing System and Axotouch®
Two-Point Discriminator. These evaluation and measurement tools
assist health care professionals in detecting changes in sensation,
assessing return of sensory, grip, and pinch function, evaluating
effective treatment interventions, and providing feedback to
patients on peripheral nerve function. The Axogen portfolio of
products is available in the United States, Canada, the United
Kingdom, and several other European and international
countries.
Contact:Axogen, Inc.Pete
Mariani, Chief Financial
Officerpmariani@axogeninc.comInvestorRelations@axogeninc.com
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Apr 2023 to Apr 2024